The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1319
Safety of Smoking Cessation Drugs
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The most effective drugs available for treatment of tobacco dependence are bupropion (Zyban, and others) and varenicline (Chantix).1 The FDA recently ordered the manufacturers of both to add boxed warnings about the risk of psychiatric symptoms and suicide to their prescribing information (FDA Alert, 7/1/2009).

BUPROPION — In one randomized, double-blind trial, smoking cessation rates after 6 months were 35% with bupropion alone and 39% with bupropion plus nicotine.2 The drug’s most common adverse effects have been insomnia and dry mouth; weight gain with bupropion has been less than with placebo.

VARENICLINE — Varenicline is now generally considered the most effective drug available for treatment of tobacco dependence.3 In one 6-month maintenance study, among patients who had quit smoking after 12 weeks ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Safety of Smoking Cessation Drugs
Article code: 1319a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian